. 2023 Oct 11;34(11):1951–2000. doi: 10.1021/acs.bioconjchem.3c00374

Table 3. Highlighted ADC Clinical Trials with Solid Tumor Indications in the Development Pipeline.

ADC intervention	Sponsor	Solid tumor indications	Target	NCT number	Clinical trial phase
ABBV-400	AbbVie	Non-Small Cell Lung Cancer\|Gastresophageal Cancer\|Colorectal Cancer	cMET	NCT05029882	Phase I
ADCT-901	ADC Therapeutics	Advanced Solid Tumors	KAAG1	NCT04972981	Phase I
ARX517	Ambrx	Advanced Solid Tumors	PSMA	NCT04662580	Phase I
ASN004	Kirilys Therapeutics	Solid Tumors	5T4	NCT04410224	Phase I
AZD9592	AstraZeneca	Non-Small Cell Lung Cancer\|Head and Neck Cancer	cMET l EGFR(bispecific)	NCT05647122	Phase I
BAY-2315497	Bayer	Prostate Cancer	PSMA	NCT03724747	Phase I
BYON3521	Byondis	Solid Tumors	cMET	NCT05323045	Phase I
CMG901	Keymed Biosciences Co.	Gastric Cancer l Pancreatic Cancer	Claudin 18.2	NCT04805307	Phase I
DS-6000a	Daiichi Sankyo	Renal Cell Carcinoma\| Gynecologic Cancer	CDH6	NCT04707248	Phase I
HS-20093	Shanghai Hansoh Biomedical Co.	Advanced Solid Tumors	B7H3	NCT05276609	Phase I
IBI-343	Innovent Biologics	Advanced Solid Tumors	Claudin 18.2	NCT05458219	Phase I
IMGN151	ImmunoGen	Gynecologic Cancer	FRα	NCT05527184	Phase I
M1231	EMD Serono Research and Development Institute	Esophageal Cancer\| Non-Small Cell Lung Cancer	MUC1-EGFR (bispecific)	NCT04695847	Phase I
MYTX-011	Mythic Therapeutics	Lung Cancer	cMET	NCT05652868	Phase I
ORM-5029	Orum Therapeutics	HER2-positive Breast Cancer	HER2	NCT05511844	Phase I
PYX-201	Pyxis Oncology	Advanced Solid Tumors	Extradomain B fibronectin	NCT05720117	Phase I
STRO-002	Sutro Biopharma	Gynecologic Cancer	CD74	NCT03748186	Phase I
TORL-1–23	TORL Biotherapeutics	Advanced Solid Tumor\| Gynecologic Cancer\| Lung Cancer	Claudin 18.2	NCT05103683	Phase I
XMT-1660	Mersana Therapeutics	Breast Cancer\| Gynecologic Cancer	B7H4	NCT05377996	Phase I
YL202	MediLink Therapeutics	Non-Small Cell Lung Cancer\| Breast Cancer	HER3	NCT05653752	Phase I
Zanidatamab Zovodotin	Zymeworks	HER2-expressing Cancers	HER2 domain II l HER2 domain IV (Bispecific)	NCT03821233	Phase I
9MW2821	Mabwell	Solid Tumors	Nectin-4	NCT05216965	Phase I \|Phase II
AZD8205	AstraZeneca	Breast Cancer\|Biliary Tract Carcinoma\| Gynecologic Cancer	B7H4	NCT05123482	Phase I \|Phase II
BB-1705	Bliss Biopharmaceutical (Hangzhou) Co.	Solid Tumor	EGFR	NCT05217693	Phase I \|Phase II
BDC-1001	Bolt Biotherapeutics	HER2 Positive Solid Tumors	HER2	NCT04278144	Phase I \|Phase II
BIO-106	BiOneCure Therapeutics	Advanced Solid Tumor	TROP2	NCT05320588	Phase I \|Phase II
DB-1303	DualityBio	HER2 Positive Advanced Solid Tumor	HER2	NCT05150691	Phase I \|Phase II
FOR46	Fortis Therapeutics	Prostate Cancer	CD46	NCT05011188	Phase I \|Phase II
LM-302	Turning Point Therapeutics	Advanced Solid Tumor	Claudin 18.2	NCT05001516	Phase I \|Phase II
MRG004A	Shanghai Miracogen	Advanced or Metastatic Solid Tumors	Tissue Factor	NCT04843709	Phase I \|Phase II
NBE-002	NBE-Therapeutics	Breast Cancer	ROR1	NCT04441099	Phase I \|Phase II
OBI-999	OBI Pharma	Advanced Solid Tumor	Globo H	NCT04084366	Phase I \|Phase II
Ozuriftamab Vedotin	BioAtla	Non-Small Cell Lung Cancer\| Triple Negative Breast Cancer\| Melanoma\| Head and Neck Cancer	ROR2	NCT03504488	Phase I \|Phase II
PRO1184	ProfoundBio	Gynecologic Cancer\| Lung Cancer \| Breast Cancer	FRα	NCT05579366	Phase I \|Phase II
REGN5093	Regeneron Pharmaceuticals	NSCLC	cMET l CMET (Bispecific)	NCT04077099	Phase I \|Phase II
SKB264	Klus Pharma	Gynecologic Cancer\| Gastric Cancer\| Bladder Cancer\| Lung Cancer\| Head and Neck Cancer\| Breast Cancer	TROP2	NCT04152499	Phase I \|Phase II
SOT102	SOTIO Biotech	Gastric Cancer\| Pancreatic Cancer	Claudin 18.2	NCT05525286	Phase I \|Phase II
W0101	Pierre Fabre	Advanced or Metastatic Solid Tumors	IGF-1R	NCT03316638	Phase I \|Phase II
Zilovertamab vedotin	Merck	Bladder Carcinoma	ROR1	NCT05562830	Phase I \|Phase II
Mecbotamab Vedotin	BioAtla	Non-Small Cell Lung Cancer	AXL	NCT04681131	Phase II
CX-2009	CytomX Therapeutics	Breast Cancer	CD166	NCT04596150	Phase II
MORAb-202	Bristol-Myers Squibb	Non-Small Cell Lung Cancer	Fos-related antigen	NCT05577715	Phase II
RC108	RemeGen Co.	Gastric Cancer	cMET	NCT05628857	Phase II
Vobramitamab Duocarmazine	MacroGenics	Prostate Cancer	B7H3	NCT05551117	Phase II
ARX78	Jiangsu HengRui Medicine Co.	HER2-positive Breast Cancer	HER2	NCT05426486	Phase II \|Phase III
Enfortumab Vedotin	Astellas Pharma	Bladder Cancer	Nectin-4	NCT03474107	Phase III
Mirvetuximab Soravtansine	ImmunoGen	Gynecologic Cancer	FRα	NCT04209855	Phase III
MRG002	Shanghai Miracogen	Advanced or Metastatic Urothelium Cancer	HER2	NCT05754853	Phase III
Patritumab Deruxtecan	Daiichi Sankyo	Nonsmall Cell Lung Cancer	HER3	NCT05338970	Phase III
RC48	RemeGen Co.	Bladder Cancer	HER	NCT05302284	Phase III
SAR-408701	Sanofi	Non-Small Cell Lung Cancer Metastatic	CEACAM5	NCT04154956	Phase III
Telisotuzumab Vedotin	AbbVie	Non-Small Cell Lung Cancer	cMET	NCT04928846	Phase III
Tisotumab Vedotin	Seagen	Gynecologic Cancer	Tissue Factor	NCT04697628	Phase III
Trastuzumab Emtansine	Hoffmann-La Roche	Breast Cancer	HER2	NCT01772472	Phase III
Trastuzumab Duocarmazine	Byondis	Metastatic Breast Cancer	HER2	NCT03262935	Phase III
Upifitimab Rilsodotin	Mersana Therapeutics	Gynecologic Cancer	NaPi2b	NCT05329545	Phase III
Sacituzumab Govitecan	Gilead Sciences	Solid Tumors	TROP2	NCT04319198	Phase IV